FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”
In Brief: Shingleton Chairs Cancer Control Committee; Joftes, Price Head Review, Organ Site Branches
NDA For MeCCNU Turned Down By Oncologic Drugs Advisory Committee
Schepartz New DCT Deputy Director; DeVita To Continue As Clinical Director
Nine Cancer Act Changes Considered By NCAB Subcommittee
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - Alec Kimmelman announced as next CEO and Dean of NYU Langone Health